Arecor Therapeutics (LON:AREC) Shares Down 3.1% – What’s Next?

Arecor Therapeutics plc (LON:AREC – Get Free Report) shares were down 3.1% during mid-day trading on Friday . The company traded as low as GBX 60.12 and last traded at GBX 61.50. Approximately 59,482 shares changed hands during mid-day trading, an increase of 201% from the average daily volume of 19,749 shares. The stock had previously closed at GBX 63.50.

Arecor Therapeutics Price Performance

The firm has a market cap of £23.22 million, a PE ratio of 30.75 and a beta of -0.18. The company has a debt-to-equity ratio of 1.52, a current ratio of 4.35 and a quick ratio of 6.24. The firm has a 50-day simple moving average of GBX 64.09 and a 200 day simple moving average of GBX 69.29.

About Arecor Therapeutics

(Get Free Report)

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.

Further Reading

• Five stocks we like better than Arecor Therapeutics
• Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
• Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
• Apple’s Record Quarter Could Not Outrun Its Guidance Problem
• McKesson’s Compounding Keeps Adding Up